Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2020; 74(6): 547–551. doi: 10.48095/ccgh2020547.

Proton pump inhibitors – do we know them well and are they really that safe? – part 2

Jan Bultas1

+ Affiliation


To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

27. Moayyedi P, Eikelboom JW, Bosch J et al. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-control led trial. Gastroenterology 2019; 157 (2): 403–412. doi: 10.1053/j.gastro.2019.04.041.
28. Melloni C, Washam JB, Jones WS et al. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: a systematic review. Circ Cardiovasc Qual Outcomes 2015; 8 (1): 47–55. doi: 10.1161/ CIRCOUTCOMES.114.001177.
29. Khan SU, Lone AN, Asad ZU et al. Meta-analysis of efficacy and safety of proton pump inhibitors with dual antiplatelet therapy for coronary artery disease. Cardiovasc Revasc Med 2019; 20 (12): 1125–1133. doi: 10.1016/j.carrev.2019.02.002.
30. Scally B, Emberson JR, Spata E et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018; 3 (4): 231–241. doi: 10.1016/S2468-1253 (18) 30 037-2.
31. Miyazaki H, Igarashi A, Takeuchi T et al. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: a systematic review. J Gastroenterol Hepatol 2019; 34 (8): 1316–1328. doi: 10.1111/jgh. 14664.
32. Gotoh Y, Ishibashi E, Honda S et al. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease. Medicine (Baltimore) 2020; 99 (11): e19520. doi: 10.1097/MD.000000 0000019520.
33. Lyu QJ, Pu QH, Zhong XF et al. Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for helicobacter pylori eradication: A meta-analysis of randomized clinical trials. Biomed Res Int 2019; 9781212. doi: 10.1155/2019/9781 212.
34. Tsujita K, Deguchi H, Uda A et al. Upper gastrointestinal bleeding in Japanese patients with ischemic heart disease receiving vonoprazan or a proton pump inhibitor with multiple antithrombotic agents: A nationwide database study. J Cardiol 2020; pii: S0914–5087 (20) 30068-X. dtzi: 10.1016/j.jjcc.2020.02.012.
35. Ray WA, Chung CP, Murray KT et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA 2018; 320 (21): 2221–2230. doi: 10.1001/jama.2018.17242.
36. Státní ústav pro kontrolu léčiv. 2020 [online]. Dostupné z: http: //www.sukl.cz/modules/medication/detail.php?code=0192580&tab= prices.
37. Makunts T, Cohen IV, Awdishu L et al. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities and nephrolithiasis. Sci Rep 2019; 9 (1): 2282. 10.1038/s41598-019-39335-7.


Kreditovaný autodidaktický test